Outlook Atomo continues to focus on core growth drivers, including: * Obtaining regulatory approvals to facilitate commencement of device sales from key international contracts with Access Bio and DIVOC Labs for North America and India, respectively * Pursuing opportunities in Australia for sale of a combination rapid COVID-19 screen (both antigen and antibody testing) into the local market * Continued scale up of business in the HIV self-test market and in particular, supporting potential global tender opportunities being pursued by Atomo partner, Mylan * Expansion of sales efforts related to OEM contracts, especially in North America to existing and new OEM customers * Developing and expanding new Atomo rapid diagnostic finished products and entry into new point of care test markets, in partnership with certain existing customers in strategic channels * Launch of Atomo’s new digital health solutions that integrate with Atomo’s devices, including a low-cost digital reader and a User App, to support the continued rollout of rapid testing in community and consumer settings
65% up in revenue from last quarter is pretty good.
AT1 Price at posting:
33.0¢ Sentiment: Hold Disclosure: Held
